Medical Crossfire®: Treating MS in the Modern Era: Right Patient, Right Treatment, Right Time

Released On
April 20, 2019

Expires On
April 20, 2020

Media Type

Completion Time
90 minutes

Neurology, Rheumatology, Physiatry, Genetics


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


Supported by educational grants from Biogen, Genentech, and Sanofi Genzyme.


Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits
  • Nurses — 1.5 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, primary care physicians, nurse practitioners, physician assistants, and other health care professionals who treat patients with MS.

Program Overview

This Medical Crossfire® activity describes the importance of early diagnosis and treatment of multiple sclerosis (MS) and the design of efficacious treatment strategies, as well as shares the experts’ personal approaches to overall management of MS. The panelists will review current and emergent therapies, including their insights from recent clinical trials, and how these agents might be employed as they enter the clinical armamentarium. This activity will provide clinicians with an in-depth understanding of approved therapies for different MS disease phenotypes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the importance of early diagnosis and treatment of MS using efficacious disease-modifying therapy (DMT)
  • Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS
  • Analyze data from recent clinical trials to determine the role of novel DMTs in the existing treatment landscape and the potential for improving clinical outcomes


Bruce A. Cohen, MD (Chair)

Professor, Davee Department of Neurology and Clinical Neurological Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Clyde E. Markowitz, MD

Director, Multiple Sclerosis Center
Associate Professor, Neurology
Perlman School of Medicine, University of Pennsylvania
Philadelphia, PA

Lauren Krupp, MD

Director, Multiple Sclerosis Comprehensive Care Center
Professor, Neurology
NYU Langone Health
New York, NY

Aliza Ben-Zacharia, DrNP, ANP, PhDc

Assistant Professor, Neurology
The Corrine Goldsmith Dickinson Center for Multiple Sclerosis
Associate Director, Center of Nursing Research and Innovation
Mount Sinai Medical Center
New York, NY

Accreditation Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours

Disclosures of Conflicts of Interest

Bruce A. Cohen, MD

  • Grant/Research Support: Hoffmann-La Roche, Genentech, MedDay
  • Consultant: Biogen, Celgene, EMD Serono

Clyde E. Markowitz, MD

  • Consultant: Biogen, Bayer, Teva, EMD Serono, Novartis, Sanofi Genzyme, Genentech, Celgene, Alexion, Roche, Actelion

Lauren Krupp, MD

  • Grant/Research Support: Biogen, Novartis
  • Consultant: Sanofi-Aventis, Novartis, EMD Serono, Genzyme, Roche

Aliza Ben-Zacharia, DrNP, ANP, PhDc

  • Grant/Research Support: Biogen, Novartis
  • Consultant: Biogen, EMD Serono, Genentech, Genzyme, Novartis

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for This Activity and Receiving Credit

  1. You will need to log in to participate in the activity.
  2. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  3. At the end of the activity, educational content/audio files will be available for your reference.
  4. In order to receive a CME/CE certificate, you must complete the activity.
  5. Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

TThis CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.